Response to antiplatelet treatment: from genes to outcome

Lancet. 2010 Oct 16;376(9749):1278-81. doi: 10.1016/S0140-6736(10)61313-X.
No abstract available

Publication types

  • Comment

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / genetics*
  • Acute Coronary Syndrome / therapy
  • Angioplasty, Balloon, Coronary
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aspirin / administration & dosage
  • Aspirin / adverse effects
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Humans
  • Pharmacogenetics
  • Piperazines / administration & dosage
  • Piperazines / adverse effects
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects*
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Polymorphism, Single Nucleotide
  • Prasugrel Hydrochloride
  • Stents
  • Thiophenes / administration & dosage
  • Thiophenes / adverse effects
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Piperazines
  • Platelet Aggregation Inhibitors
  • Thiophenes
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Prasugrel Hydrochloride
  • Ticlopidine
  • Aspirin